{"id":"bbv154-intranasal-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasal congestion"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses a recombinant viral vector platform administered intranasally to induce both mucosal (IgA) and systemic (IgG) antibody responses, as well as T-cell immunity. By targeting the respiratory mucosa directly, it aims to provide protection at the site of viral entry and establish broader immune memory against COVID-19.","oneSentence":"BBV154 is an intranasal recombinant vaccine that stimulates mucosal and systemic immune responses against SARS-CoV-2 by delivering viral antigens directly to respiratory tract tissues.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:39.197Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention (intranasal booster or primary series)"}]},"trialDetails":[{"nctId":"NCT05639998","phase":"PHASE2","title":"BBV152/BBV154 Heterologus Prime-Boost Study","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2021-09-01","conditions":"Corona Virus Infection","enrollment":608},{"nctId":"NCT05567471","phase":"PHASE3","title":"Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2022-02-26","conditions":"COVID-19 Respiratory Infection","enrollment":875},{"nctId":"NCT05522335","phase":"PHASE3","title":"Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers","status":"UNKNOWN","sponsor":"Bharat Biotech International Limited","startDate":"2022-04-16","conditions":"COVID-19 Respiratory Infection","enrollment":3160},{"nctId":"NCT04751682","phase":"PHASE1","title":"Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2021-03-01","conditions":"SARS-CoV Infection","enrollment":175}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BBV154 Intranasal Vaccine","genericName":"BBV154 Intranasal Vaccine","companyName":"Bharat Biotech International Limited","companyId":"bharat-biotech-international-limited","modality":"Biologic","firstApprovalDate":"","aiSummary":"BBV154 is an intranasal recombinant vaccine that stimulates mucosal and systemic immune responses against SARS-CoV-2 by delivering viral antigens directly to respiratory tract tissues. Used for COVID-19 prevention (intranasal booster or primary series).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}